Occam Recruits Kim Blackwell to Board of NVIDIA-Backed Charm Therapeutics
In September 2025, Occam Global recruited Kim Blackwell, MD, to the Board of CHARM Therapeutics.
Kim was most recently CEO of Zentalis Pharmaceuticals, a public, clinical-stage oncology company, and previously served as Chief Medical Officer at Tempus. She joins the board as a non-executive director, bringing extensive oncology and clinical development experience, which will be crucial for the advancement of CHARM’s clinical program.
Kim earned a Bachelor's degree in Bioethics/Medical Ethics from Duke University and her MD from the Mayo Clinic Alix School of Medicine.
Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.